These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 28737291)

  • 21. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
    Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
    Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients.
    Di Biagio A; Ricci E; Viscoli C; Mesini A; Menzaghi B; Carenzi L; Orofino G; Parruti G; Martinelli C; Madeddu G; De Socio GV; Franzetti M; Quirino T; Bonfanti P;
    Curr HIV Res; 2013 Apr; 11(3):179-86. PubMed ID: 23432466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis.
    Chowers M; Gottesman BS; Leibovici L; Schapiro JM; Paul M
    Eur J Clin Microbiol Infect Dis; 2010 Jul; 29(7):779-86. PubMed ID: 20449621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection.
    Wonganan P; Limpanasithikul W; Jianmongkol S; Kerr SJ; Ruxrungtham K
    Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):551-564. PubMed ID: 32508203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor.
    Spertilli Raffaelli C; Rossetti B; Paglicci L; Colafigli M; Punzi G; Borghi V; Pecorari M; Santoro MM; Penco G; Antinori A; Zazzi M; De Luca A; Zanelli G
    J Antimicrob Chemother; 2018 Sep; 73(9):2480-2484. PubMed ID: 29945251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
    Fabbiani M; Mondi A; Colafigli M; D'Ettorre G; Paoletti F; D'Avino A; Ciccarelli N; Sidella L; Murri R; Fortuna S; Vullo V; Cauda R; De Luca A; Di Giambenedetto S
    Scand J Infect Dis; 2014 Jan; 46(1):34-45. PubMed ID: 24161018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial.
    Girard PM; Antinori A; Arribas JR; Ripamonti D; Bicer C; Netzle-Sveine B; Hadacek B; Moecklinghoff C
    HIV Med; 2017 Jan; 18(1):5-12. PubMed ID: 27279571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
    Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
    HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triple nucleoside reverse transcriptase inhibitor therapy in children.
    Handforth J; Sharland M
    Paediatr Drugs; 2004; 6(3):147-59. PubMed ID: 15170362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients.
    Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Lin KY; Huang YC; Su YC; Liu WC; Hung CC
    Int J Antimicrob Agents; 2019 Jul; 54(1):35-42. PubMed ID: 30905695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
    Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
    Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. State of the Art of Dual Therapy in 2015.
    Nozza S; Svicher V; Saracino A; d'Ettorre G; De Luca A; Maggiolo F; Bonora S; di Biagio A; Rusconi S; Mussini C
    AIDS Rev; 2015; 17(3):127-34. PubMed ID: 26450801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations.
    Sörstedt E; Carlander C; Flamholc L; Hejdeman B; Svedhem V; Sönnerborg A; Gisslén M; Yilmaz A
    Int J Antimicrob Agents; 2018 May; 51(5):733-738. PubMed ID: 29371105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pediatric Neurodevelopmental Functioning After In Utero Exposure to Triple-NRTI vs. Dual-NRTI + PI ART in a Randomized Trial, Botswana.
    Kacanek D; Williams PL; Mayondi G; Holding P; Leidner J; Moabi K; Tepper V; Nichols S; Makhema J; Jibril H; Madidimalo T; Shapiro R; Lockman S; Kammerer B
    J Acquir Immune Defic Syndr; 2018 Nov; 79(3):e93-e100. PubMed ID: 30015793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of integrase inhibitors vs protease inhibitors is associated with improved HIV viral suppression.
    Kleinmann WN; Pruszynski JE; Adhikari EH
    Am J Obstet Gynecol MFM; 2023 Nov; 5(11):101151. PubMed ID: 37689245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
    Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
    AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
    Domingo P; Ribera E
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.